Listeria-vectored multi-antigenic tuberculosis vaccine protects C57BL/6 and BALB/c mice and guinea pigs against Mycobacterium tuberculosis challenge

[1]  M. Horwitz,et al.  Listeria-Vectored Multiantigenic Tuberculosis Vaccine Enhances Protective Immunity against Aerosol Challenge with Virulent Mycobacterium tuberculosis in BCG-Immunized C57BL/6 and BALB/c Mice , 2022, mBio.

[2]  S. Behar,et al.  CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection , 2021, bioRxiv.

[3]  D. Portnoy,et al.  Why is Listeria monocytogenes such a potent inducer of CD8+ T‐cells? , 2020, Cellular microbiology.

[4]  R. Walker,et al.  The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial , 2018, npj Vaccines.

[5]  M. Tameris,et al.  Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  T. Ottenhoff,et al.  Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. , 2017, Vaccine.

[7]  M. Hatherill,et al.  H1:IC31 vaccination is safe and induces long-lived TNF-α+IL-2+CD4 T cell responses in M. tuberculosis infected and uninfected adolescents: A randomized trial. , 2017, Vaccine.

[8]  Richard G. White,et al.  Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries , 2014, Proceedings of the National Academy of Sciences.

[9]  S. Kaufmann,et al.  Safety and immunogenicity of the recombinant BCG vaccine VPM1002 in a phase 1 open-label randomized clinical trial. , 2013, Vaccine.

[10]  P. Andersen,et al.  The HyVac4 Subunit Vaccine Efficiently Boosts BCG-Primed Anti-Mycobacterial Protective Immunity , 2012, PloS one.

[11]  J. Lieberman,et al.  Prior exposure to an attenuated Listeria vaccine does not reduce immunogenicity: pre-clinical assessment of the efficacy of a Listeria vaccine in the induction of immune responses against HIV , 2011, Journal of immune based therapies and vaccines.

[12]  Sylvie Bertholet,et al.  A Defined Tuberculosis Vaccine Candidate Boosts BCG and Protects Against Multidrug-Resistant Mycobacterium tuberculosis , 2010, Science Translational Medicine.

[13]  I. Dégano,et al.  Resistance to mycobacterial infection: a pattern of early immune responses leads to a better control of pulmonary infection in C57BL/6 compared with BALB/c mice. , 2009, Vaccine.

[14]  William R. Jacobs,et al.  A Critical Role for CD8 T Cells in a Nonhuman Primate Model of Tuberculosis , 2009, PLoS pathogens.

[15]  G. Kaplan,et al.  A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers. , 2008, The Journal of infectious diseases.

[16]  R. Rappuoli,et al.  Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guérin Immunity1 , 2006, The Journal of Immunology.

[17]  M. Horwitz,et al.  Extraordinarily few organisms of a live recombinant BCG vaccine against tuberculosis induce maximal cell-mediated and protective immunity. , 2006, Vaccine.

[18]  M. Giedlin,et al.  Listeria-based cancer vaccines that segregate immunogenicity from toxicity. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  S. Reed,et al.  Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1 , 2004, The Journal of Immunology.

[20]  H. McShane,et al.  Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective , 2003 .

[21]  M. Horwitz,et al.  Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model. , 2000, Proceedings of the National Academy of Sciences of the United States of America.